Showing results (141-150 of 191) with videos related to
Sort By:
Pageof 20
Lung Cancer (Amsterdam, Netherlands)|April 16, 2024
Long-term follow-up and exploratory analysis of lenvatinib in patients with metastatic or recurrent thymic carcinoma: Results from the multicenter, phase 2 REMORA trialSeiji Niho, Jun Sato, Miyako Satouchi, et al.Lung Cancer (Amsterdam, Netherlands)|March 13, 2023
Impact of ramucirumab pharmacokinetics in combination with docetaxel on the efficacy and survival in patients with advanced non-small cell lung cancerKazumasa Akagi, Shigehiro Yagishita, Mayu Ohuchi, et al.Japanese Journal of Clinical Oncology|April 21, 2021
Feasibility of next-generation sequencing (Oncomine™ DX Target Test) for the screening of oncogenic mutations in advanced non-small-cell lung cancer patientsYuki Takeyasu, Tatsuya Yoshida, Noriko Motoi, et al.Lung Cancer (Amsterdam, Netherlands)|September 18, 2022
Early change in the clearance of pembrolizumab reflects the survival and therapeutic response: A population pharmacokinetic analysis in real-world non-small cell lung cancer patientsMayu Ohuchi, Shigehiro Yagishita, Hitomi Jo, et al.British Journal of Cancer|November 30, 2020
Prognostic impact of peripheral blood neutrophil to lymphocyte ratio in advanced-stage pulmonary large cell neuroendocrine carcinoma and its association with the immune-related tumour microenvironmentMasayuki Shirasawa, Tatsuya Yoshida, Hidehito Horinouchi, et al.Translational Lung Cancer Research|July 10, 2023
Concordance between cryobiopsy and forceps biopsy specimens in assessment of immunohistochemistry staining for non-small cell lung carcinomaKanako Nishimatsu, Yuji Matsumoto, Jumpei Kashima, et al.European Journal of Cancer (Oxford, England : 1990)|July 16, 2015
A prospective, multicentre phase II trial of low-dose erlotinib in non-small cell lung cancer patients with EGFR mutations pretreated with chemotherapy: Thoracic Oncology Research Group 0911Kazuhiko Yamada, Hiromi Aono, Yukio Hosomi, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 5, 2022
Safety Implications of Switching Pembrolizumab Dosage From 200 mg Every 3 Weeks to 400 mg Every 6 Weeks in Patients With Advanced NSCLCRyoko Inaba Higashiyama, Tatsuya Yoshida, Shigehiro Yagishita, et al.Journal for Immunotherapy of Cancer|June 29, 2026
Pharmacokinetic variability with pembrolizumab dosage switching and its impact on immune-related adverse events in patients with non-small cell lung cancerRyoko Inaba Higashiyama, Tatsuya Yoshida, Shigehiro Yagishita, et al.European Journal of Cancer (Oxford, England : 1990)|December 22, 2021
Baseline PD-L1 expression and tumour-infiltrated lymphocyte status predict the efficacy of durvalumab consolidation therapy after chemoradiotherapy in unresectable locally advanced patients with non-small-cell lung cancerMasayuki Shirasawa, Tatsuya Yoshida, Tatsuya Imabayashi, et al.Pageof 20